Medibio completes heavily oversubscribed institutional placement for $13.9 million to accelerate commercialisation
- Placement completed, with oversubscriptions accepted up to $13.9 Million
- Fidelity Investments follows on to maintain 10.6% ownership of the Company
- IFM Investors and Regal FM to become substantial shareholders post-transaction
- Medibio now fully funded to pursue aggressive commercialisation and IP strategy
SYDNEY, Australia and MINNEAPOLIS, Oct. 12, 2017 (GLOBE NEWSWIRE) -- Medibio Limited (ASX:MEB)(OTCQB:MDBIF) is pleased to announce that it has received firm commitments to raise $13.9 million via the placement of 38,736,640 ordinary shares at a price of $0.36 per share. The placement will be conducted in a single tranche using the Company's existing placement capacity under ASX Listing Rule 7.1 and 7.1A.
The funds will allow the Company to:
- Build out organisational infrastructure for product commercialisation
- Establish requirements and testing of products and products under development for future market verticals
- Development of technology platform and infrastructure, including engineering capability, to support commercialisation
- Position Medibio for regulatory approvals on future products
Aesir Capital Pty Ltd acted as Sole Lead Manager to the transaction.
About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), and U.S. offices in Minneapolis, MN and Palo Alto, CA. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market www.otcmarkets.com and www.asx.com.au .
Additional disclosure required by listing rule 3.10.5A
In accordance with listing rule 3.10.5A in relation to shares issued under the Company's 7.1A capacity details of the placement are:
Effect of raising
The effect of the announced raising on the capital structure of the Company is set out below.
|Shares currently on issue||156,196,558|
|Shares to be issued under LR7.1 placement capacity||23,141,984||14.82||%|
|Shares to be issued under LR7.1A placement capacity||15,594,656||9.98||%|
|Total Shares on issue after completion of the Placement||194,933,198||24.80||%|
The Company believes the benefits from funds raised in this placement at a discount to the 15-day VWAP of 11.9% outweigh the inability of shareholders to participate. The placement was not underwritten and direct costs of the raising are up to 7.5% of funds raised.
Further Information: Website: www.medibio.com.au
Medibio Shareholder Enquiries:
CEO and Managing Director
T: +1 (952) 465 4787
Australian Media Enquiries:
T: +61 (0) 412 036 231
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
Crown Bioscience Inc.17.11.2017 18:09 | pressemeddelelse
CrownBio Launches an Innovative Grant Program to Fund Advancements in Preclinical Oncology Research
Barings17.11.2017 17:02 | pressemeddelelse
Barings Backs Sentinel Capital Partners in Acquisition of Nekoosa
Vicor Corporation16.11.2017 23:31 | pressemeddelelse
At SC17, ExaScaler and PEZY Computing Unveil Gyoukou Supercomputer with a High Combined Green500/Top500 Ranking
ELS Educational Services, Inc.16.11.2017 21:01 | pressemeddelelse
ELS Educational Services, Inc. Launches New Vacation English Program Starting January 2018
Aryaka16.11.2017 16:04 | pressemeddelelse
Global SD-WAN Partnership between CallTower and Aryaka to Deliver High-Performance Cloud Communication Solutions to Global Enterprises
Gunvor Group Ltd16.11.2017 15:01 | pressemeddelelse
Gunvor Secures US $1.39 Billion Revolving Credit Facility
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum